Apomorphine in the treatment of Parkinson's disease: a review
暂无分享,去创建一个
[1] T. van Laar,et al. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study. , 2017, Parkinsonism & related disorders.
[2] Á. Sesar,et al. Continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease: 10-year experience with 230 patients , 2017, Journal of Neurology.
[3] M. Vérin,et al. Apomorphine pump in advanced Parkinson's disease: Effects on motor and nonmotor symptoms with brain metabolism correlations , 2017, Journal of the Neurological Sciences.
[4] W. Poewe,et al. Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. , 2016, Parkinsonism & related disorders.
[5] K. Ray Chaudhuri,et al. Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future , 2016, npj Parkinson's Disease.
[6] M. Lanotte,et al. Advanced therapies in Parkinson's disease: Long-term retrospective study. , 2016, Parkinsonism & related disorders.
[7] A. Lees,et al. Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence. , 2016, Parkinsonism & related disorders.
[8] A. Fasano,et al. 24‐Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[9] E. Dietrichs,et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. , 2015, Parkinsonism & related disorders.
[10] M. Okun,et al. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson’s disease , 2015, Expert opinion on pharmacotherapy.
[11] G. Deuschl,et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations. , 2015, Parkinsonism & related disorders.
[12] C. Redecker,et al. Advanced stages of PD: interventional therapies and related patient-centered care , 2015, Journal of Neural Transmission.
[13] T. Henriksen. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians. , 2014, Neurodegenerative disease management.
[14] C. N. Homann,et al. The role of subcutaneous infusion of apomorphine in Parkinson’s disease , 2014, Expert review of neurotherapeutics.
[15] E. Molho,et al. Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions , 2014, Expert review of neurotherapeutics.
[16] J. Kulisevsky,et al. Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I) , 2013 .
[17] H. Reichmann,et al. Treatment of Parkinson’s disease in the advanced stage , 2013, Journal of Neural Transmission.
[18] J. Kulisevsky,et al. Advanced Parkinson ’ s disease : Clinical characteristics and treatment ( part 1 ) , 2013 .
[19] G. Deuschl,et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review , 2013, Journal of Neurology.
[20] W. Ondo,et al. Apomorphine injections: predictors of initial common adverse events and long term tolerability. , 2012, Parkinsonism & related disorders.
[21] A. Albanese,et al. Motor features and response to oral levodopa in patients with Parkinson’s disease under continuous dopaminergic infusion or deep brain stimulation , 2012, European journal of neurology.
[22] K. Chaudhuri,et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.
[23] R. Hilker,et al. What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? , 2011, Journal of Neural Transmission.
[24] F. Klostermann,et al. Benefit from jejunal levodopa in a patient with apomorphine pump , 2011, Journal of Neurology.
[25] D. Nyholm,et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations , 2009, Acta neurologica Scandinavica.
[26] S. Gunzler. Apomorphine in the treatment of Parkinson disease and other movement disorders , 2009, Expert opinion on pharmacotherapy.
[27] K. Kieburtz. Therapeutic strategies to prevent motor complications in Parkinson’s disease , 2008, Journal of neurology.
[28] Pablo Mir,et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[29] M. Stacy,et al. Apomorphine in the treatment of Parkinson's disease , 2007, Expert opinion on pharmacotherapy.
[30] L. Lopiano,et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome , 2007, Movement disorders : official journal of the Movement Disorder Society.
[31] R. Pfeiffer,et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. , 2007, Parkinsonism & related disorders.
[32] Jack J. Chen,et al. Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease , 2006, Pharmacotherapy.
[33] Andrew Evans,et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges , 2005, Movement disorders : official journal of the Movement Disorder Society.
[34] E. Tolosa,et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[35] Andrew J Lees,et al. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients , 2002, Movement disorders : official journal of the Movement Disorder Society.
[36] D. Nyholm,et al. Duodenal levodopa infusion in Parkinson's disease – long‐term experience , 2001, Acta neurologica Scandinavica.
[37] A. Lees,et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. , 2001, Brain : a journal of neurology.
[38] Use of apomorphine in Parkinson's disease. , 1999, Hospital medicine.
[39] P. Odin,et al. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up , 1998, Journal of neurology, neurosurgery, and psychiatry.
[40] A J Lees,et al. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.
[41] A. Lees,et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications , 1998, Neurology.
[42] I. McKeith,et al. Psychiatric features in diffuse Lewy body disease , 1998, Neurology.
[43] L. Metman,et al. Apomorphine responses in parkinson's disease and the pathogenesis of motor complications , 1997, Neurology.
[44] A. Lees,et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[45] A J Lees,et al. Dopamine agonists in Parkinson's disease: a look at apomorphine , 1993, Fundamental & clinical pharmacology.
[46] A. Hughes,et al. Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.
[47] A. Lees,et al. Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations. , 1991, Clinical neuropharmacology.
[48] A. Lees,et al. Intranasal apomorphine in Parkinson's disease , 1991, Neurology.
[49] A. Lees,et al. The Motor Response to Repeated Apomorphine Administration in Parkinson's Disease , 1991, Clinical neuropharmacology.
[50] A. Lees,et al. The motor response to sequential apomorphine in parkinsonian fluctuations. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[51] A. Hughes,et al. Rectal apomorphine in Parkinson's disease , 1991, The Lancet.
[52] A. Lees,et al. Intranasal apomorphine: a new treatment in Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.
[53] A. Lees,et al. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.
[54] A. Lees,et al. Apomorphine in the diagnosis and treatment of parkinsonian tremor. , 1990, Clinical neuropharmacology.
[55] A. Lees,et al. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes , 1990, The Lancet.
[56] A. Lees,et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. , 1990, Journal of neurology, neurosurgery, and psychiatry.
[57] R. Duvoisin,et al. Long‐term duodenal infusion of levodopa for motor fluctuations in parkinsonism , 1988, Annals of neurology.
[58] A. Lees,et al. SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS , 1988, The Lancet.
[59] I. Shoulson,et al. Duodenal delivery of levodopa for on‐off fluctuations in parkinsonism: Preliminary observations , 1986, Annals of neurology.
[60] A. Lees,et al. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. , 1984, Brain : a journal of neurology.
[61] M. Elian,et al. MOTOR-NEURONE DISEASE IN ISRAEL , 1975, The Lancet.
[62] G C Cotzias,et al. Similarities between neurologic effects of L-dopa and of apomorphine. , 1970, The New England journal of medicine.
[63] Schwab Rs,et al. Apomorphine in Parkinson's disease. , 1951 .
[64] J. Lettvin,et al. Apomorphine in Parkinson's disease. , 1951, Transactions of the American Neurological Association.